Navigation Links
ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
Date:6/17/2010

MOUNTAIN VIEW, Calif., June 17 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR).  CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).  Data demonstrating that CCX354 was safe and well tolerated with a clear pharmacokinetic to pharmacodynamic relationship were presented today by Daniel Dairaghi, Ph.D., Director, Molecular Pharmacology of ChemoCentryx, in a poster presentation entitled "A Novel CCR1 Antagonist CCX354-C for Rheumatoid Arthritis" in Rome, Italy.  CCX354 is currently in Phase II clinical trials for the treatment of patients with RA.

Study results showed that CCX354 was well tolerated and displayed a linear dose-exposure profile in single-dose and multiple-dose Phase I studies in healthy volunteers.  Plasma levels far exceeded those required for adequate receptor blockade.  High levels of receptor coverage (>90%) at the 12-hour time point were achieved after a single dose of 100 mg of CCX354.

"Our data and the reports of other labs now show that a high degree of CCR1 receptor coverage is essential to achieve a therapeutic effect in inflammatory diseases such as RA," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "We are very pleased that this study demonstrated the unique ability of CCX354 to selectively and sufficiently block the CCR1 receptor – objectives that other molecules in this class have been unable to achieve to date.   As such, we believe our CCR1 antagonis
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
3. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
4. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
5. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 On September 11, Pharma ... Sherley in anticipation of a session that he will lead ... Summit,” scheduled for February 17-18, 2015 in London. In ... IQ asked Dr. Sherley to respond to several questions on ... challenges to evaluating stem cell toxicity, and future trends in ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... IACRN), a non-profit organization based in Pittsburgh, ... Excellence and Safety (ACRES), a Massachusetts non-profit ... strategic alliance agreement, setting the stage for multiple ... enhance clinical research quality and safety through specialized ...
(Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
(Date:9/29/2014)... are efficient but involve a range of resource ... seed) and pine resin and a clever recycling ... a highly interesting alternative. Their study will be ... . , ,We think our discovery can open ... the batteries of the future, says Daniel Brandell, ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3Smart, eco-friendly new battery to solve problems 2
... Wisconsin-Madison , justified or otherwise, is that its academic ... has world-class scientists and well-developed mechanisms for turning their ... that commercialization takes place within a half-hour drive from ... the figures for per capita wages, unemployment and job ...
... subscribe to the theory that consumer need is what drives ... some proof. , ,In this case, the need is ... something to be desired, and the chief executive of a ... and broadband problems before. , ,Albert Chiozzi, who plans ...
... half of the nation's top 25 banks have joined an ... , a business unit of Metavante Corp ., the ... ,Twelve of the nation's largest banks now will be able ... physically convey them, a capability that was encouraged by the ...
Cached Biology Technology:Entrepreneurship grant will build strong foundation 2Entrepreneurship grant will build strong foundation 3Entrepreneurship grant will build strong foundation 4Company to operate in wireless Internet space 2
(Date:9/30/2014)... Prenatal exposure to tetrachloroethylene (PCE) in drinking water ... abruption, according to a new study led by ... , The study, published in the journal ... 1,019 unexposed pregnancies among 1,766 women in Cape ... late 1960s to the early 1980s by the ...
(Date:9/30/2014)... -- Pollution in urban and farm runoff in Hawaii ... study finds. , The study, published Tuesday in ... nitrogen in the runoff ends up in algae that ... the animals, eyes, flippers and internal organs. , Scientists ... National Oceanic and Atmospheric Administration (NOAA) conducted the study ...
(Date:9/30/2014)... trouble getting pregnanteven with IVF? Here,s some hope: A ... The FASEB Journal , explains how ... known as PAWP, which induced embryo development in human ... embryo development by the sperm cell during fertilization. , ... a major paradigm shift in our understanding of human ...
Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Synthetic sperm protein raises the chance for successful in vitro fertilization 2
... may have to exercise even harder to get the benefits ... in the February issue of the journal Cell Metabolism, published ... a kind of metabolic boost in response to exercise is ... AMP-activated protein kinase (AMPK) slows down in the skeletal muscle ...
... Having a twin sister could put male saiga antelopes at ... shows that male twins with a sister are born lighter ... optimal size for males. The research also shows that saigas ... other similar species investing more in their offspring during ...
... how much they had already eaten -- in this case, ... who had no such environmental cues, finds a new Cornell ... eating at a table where leftover bones accumulated compared with ... than for women. , "The results suggest that people ...
Cached Biology News:Power-boosting signal in muscle declines with age 2The penalty of having a sister -- why sibling sex matters for male saiga antelopes 2The penalty of having a sister -- why sibling sex matters for male saiga antelopes 3